MCM
ABBV icon

Maple Capital Management’s AbbVie ABBV Stock Holding History

Maple Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$960K Buy
3,813
+12
+0.3% +$2.58K 0.06% 60
2026
Q1 		$827K Sell
3,801
-90
-2% -$20K 0.06% 59
2025
Q4 		$889K Sell
3,891
-31
-0.8% -$7.06K 0.06% 59
2025
Q3 		$908K Hold
3,922
– – 0.06% 56
2025
Q2 		$728K Buy
3,922
+493
+14% +$91.6K 0.05% 65
2025
Q1 		$718K Buy
3,429
+1,092
+47% +$212K 0.06% 65
2024
Q4 		$415K Buy
2,337
+497
+27% +$91.4K 0.03% 83
2024
Q3 		$363K Sell
1,840
-225
-11% -$42K 0.03% 87
2024
Q2 		$354K Buy
2,065
+5
+0.2% +$828 0.03% 92
2024
Q1 		$375K Sell
2,060
-107
-5% -$18.4K 0.03% 82
2023
Q4 		$336K Buy
2,167
+805
+59% +$117K 0.03% 79
2023
Q3 		$203K Buy
+1,362
New +$200K 0.02% 94
2023
Q1 		– Sell
-1,284
Closed -$208K – 98
2022
Q4 		$208K Sell
1,284
-77
-6% -$11.8K 0.03% 92
2022
Q3 		$207K Buy
+1,361
New +$195K 0.03% 89
2022
Q2 		– Sell
-1,361
Closed -$221K – 92
2022
Q1 		$221K Buy
+1,361
New +$198K 0.03% 95
2015
Q4 		– Sell
-84,817
Closed -$4.62M – 127
2015
Q3 		$4.62M Sell
84,817
-2,960
-3% -$193K 1.71% 23
2015
Q2 		$5.9M Sell
87,777
-1,449
-2% -$94.6K 2.02% 18
2015
Q1 		$5.22M Buy
89,226
+43,828
+97% +$2.65M 1.82% 22
2014
Q4 		$2.97M Buy
45,398
+1,048
+2% +$66.1K 1.08% 38
2014
Q3 		$2.56M Sell
44,350
-1,125
-2% -$62.5K 0.97% 40
2014
Q2 		$2.57M Sell
45,475
-710
-2% -$37.2K 0.93% 44
2014
Q1 		$2.37M Sell
46,185
-1,303
-3% -$65.9K 0.92% 44
2013
Q4 		$2.51M Sell
47,488
-500
-1% -$24.6K 1% 40
2013
Q3 		$2.15M Sell
47,988
-2,930
-6% -$130K 0.95% 41
2013
Q2 		$2.1M Buy
+50,918
New +$2.23M 0.94% 43

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Maple Capital Management's ABBV Position: Q2 2026 in Review

Maple Capital Management increased its AbbVie (ABBV) stake by 0.32% in Q2 2026, buying an estimated $2.58K and bringing the position to 3,813 shares worth $960K. The position accounts for 0.06% of the portfolio, ranked #60.

Maple Capital Management first reported a position in ABBV in Q2 2013 and has held it in 25 quarters since. The position peaked at $5.9M in Q2 2015. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Maple Capital Management held 3,813 shares of AbbVie worth $960K as of Q2 2026.
  • Maple Capital Management bought 12 AbbVie shares in Q2 2026, an estimated $2.58K.
  • AbbVie made up 0.06% of Maple Capital Management's portfolio in Q2 2026, its #60 holding.
  • Maple Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 25 quarters since.
  • Maple Capital Management's AbbVie position peaked at $5.9M in Q2 2015.
  • 4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Maple Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.